Xspray Pharma AB (publ) (XSPRAY.ST)
SEK 34.0
(-2.3%)
SEK 34.0
(-2.3%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 31.94 Million SEK | 5604.82% |
| 2022 | 560 Thousand SEK | -52.74% |
| 2021 | 1.18 Million SEK | -59.11% |
| 2020 | 2.89 Million SEK | -34.93% |
| 2019 | 4.45 Million SEK | 0.0% |
| 2018 | - SEK | 0.0% |
| 2017 | - SEK | 0.0% |
| 2016 | - SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 30.57 Million SEK | 0.0% |
| 2024 Q2 | 29.85 Million SEK | 0.0% |
| 2023 Q2 | 377 Thousand SEK | -20.63% |
| 2023 Q1 | 475 Thousand SEK | -15.18% |
| 2023 Q4 | 31.94 Million SEK | 10478.48% |
| 2023 Q3 | 302 Thousand SEK | -19.89% |
| 2023 FY | 31.94 Million SEK | 5604.82% |
| 2022 Q2 | 367 Thousand SEK | -58.2% |
| 2022 Q3 | 323 Thousand SEK | -11.99% |
| 2022 Q1 | 878 Thousand SEK | -25.91% |
| 2022 FY | 560 Thousand SEK | -52.74% |
| 2022 Q4 | 560 Thousand SEK | 73.37% |
| 2021 FY | 1.18 Million SEK | -59.11% |
| 2021 Q2 | 2.11 Million SEK | -19.04% |
| 2021 Q3 | 1.66 Million SEK | -21.58% |
| 2021 Q4 | 1.18 Million SEK | -28.66% |
| 2021 Q1 | 2.61 Million SEK | -9.73% |
| 2020 Q4 | 2.89 Million SEK | -9.3% |
| 2020 FY | 2.89 Million SEK | -34.93% |
| 2020 Q3 | 3.19 Million SEK | -11.74% |
| 2020 Q2 | 3.62 Million SEK | -10.4% |
| 2020 Q1 | 4.04 Million SEK | -9.3% |
| 2019 Q3 | 5.16 Million SEK | 0.51% |
| 2019 FY | 4.45 Million SEK | 0.0% |
| 2019 Q1 | 6.63 Million SEK | 0.0% |
| 2019 Q2 | 5.13 Million SEK | -22.54% |
| 2019 Q4 | 4.45 Million SEK | -13.75% |
| 2018 Q4 | - SEK | 0.0% |
| 2018 FY | - SEK | 0.0% |
| 2018 Q1 | - SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2017 Q4 | - SEK | 0.0% |
| 2017 FY | - SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 Q4 | - SEK | 0.0% |
| 2016 FY | - SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |